Carotid-Femoral, Oscillometric and Estimated Pulse Wave Velocity
NCT ID: NCT06836622
Last Updated: 2025-02-20
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ENROLLING_BY_INVITATION
Total Enrollment
350 participants
Study Classification
OBSERVATIONAL
Study Start Date
2022-09-01
Study Completion Date
2026-03-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
What is the purpose of this research? This research aims to compare three different methods of measuring pulse wave velocity, which is the main parameter used for assessing arterial stiffness. This parameter is as important as blood pressure in predicting future cardiovascular risk.
The investigators intend to compare carotid-femoral pulse wave velocity, which is the gold standard for measuring arterial stiffness, with brachial pulse wave velocity measured using a device similar to a blood pressure monitor and a mathematical formula validated in a large European population.
Who is eligible for this survey? Anyone aged 18 or older who has been invited may participate, provided they sign an informed consent form.
Where will the field research be conducted? The research will be conducted at a health center specializing in the treatment of hypertension. This center is a reference for outpatient blood pressure monitoring in the city of Uberaba (MG), Brazil.
Which procedures will be performed by research participants? All participants who consent will answer some questions about their demographic and health information. A trained nurse will measure their weight, height, and blood pressure after a 5-minute rest, and then measure carotid-femoral pulse wave velocity. The participant will lie down on a bed and the nurse will place a sensor on the middle of their neck and the groin. The device will automatically deliver the parameters. At least three measurements are required for each participant. Measurements normally take between 10 and 15 minutes. Then, participants will wear a device to record blood pressure and pulse wave velocity for 24 hours. The nurse will fit the cuff around the participant's arm and attach the monitoring device to a belt around their waist. The device will take measurements every 20 to 30 minutes. 24 hours later, the participant must return to the research venue to have the equipment removed.
What are the risks and adverse events of the procedures? There are no known risks or adverse events (AEs) associated with carotid-femoral pulse wave velocity measurements. The risks of this research are minimal, limited to discomfort during the AMBP recording, which occurs at a low frequency. However, excessive arm pain, allergic reactions, and edema may occur. To minimize these risks, a nurse will be available via telephone to aid all participants during the AMBP recordings.
The investigators intend to compare carotid-femoral pulse wave velocity, which is the gold standard for measuring arterial stiffness, with brachial pulse wave velocity measured using a device similar to a blood pressure monitor and a mathematical formula validated in a large European population.
Who is eligible for this survey? Anyone aged 18 or older who has been invited may participate, provided they sign an informed consent form.
Where will the field research be conducted? The research will be conducted at a health center specializing in the treatment of hypertension. This center is a reference for outpatient blood pressure monitoring in the city of Uberaba (MG), Brazil.
Which procedures will be performed by research participants? All participants who consent will answer some questions about their demographic and health information. A trained nurse will measure their weight, height, and blood pressure after a 5-minute rest, and then measure carotid-femoral pulse wave velocity. The participant will lie down on a bed and the nurse will place a sensor on the middle of their neck and the groin. The device will automatically deliver the parameters. At least three measurements are required for each participant. Measurements normally take between 10 and 15 minutes. Then, participants will wear a device to record blood pressure and pulse wave velocity for 24 hours. The nurse will fit the cuff around the participant's arm and attach the monitoring device to a belt around their waist. The device will take measurements every 20 to 30 minutes. 24 hours later, the participant must return to the research venue to have the equipment removed.
What are the risks and adverse events of the procedures? There are no known risks or adverse events (AEs) associated with carotid-femoral pulse wave velocity measurements. The risks of this research are minimal, limited to discomfort during the AMBP recording, which occurs at a low frequency. However, excessive arm pain, allergic reactions, and edema may occur. To minimize these risks, a nurse will be available via telephone to aid all participants during the AMBP recordings.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Abdominal Aorta Palpation With Point of Care Ultrasound Imaging Measurements
NCT06211946
Physical Examination
Ultrasound Imaging
Abdominal Aortic Aneurysm
COMPLETED
Evaluation of Doppler Flow From the Femoral Artery as a Reflection of Cardiac Flow in a Vascular Fluid Test
NCT02878369
Acute Circulatory Failure
UNKNOWN
New Technologies to Determine Carotid Plaque Vulnerability in Patients With Significant Carotid Plaques
NCT03335033
Carotid Artery Plaque
COMPLETED
PHASE2
Effects of Different Intra-arterial Catheter Size on Frequency of Optimal Dynamic Response in Radial Arterial Waveform
NCT03642756
Catheters
UNKNOWN
NA
Efficacy of Subclavian Vein/Artery Diameter Index in Predicting the Incidence of the Spinal-Induced Hypotension in Geriatric Patients
NCT07286422
Spinal Induced Hypotension
Old Age; Debility
NOT_YET_RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
•BACKGROUND It is estimated that 1 in 4 adults suffers from hypertension, including 40% of those over the age of 25. Blood pressure tends to be higher in older adults, and in developed countries, an estimated 9 in 10 adults who live to 80 years of age will develop hypertension. Over the decades, data have shown a positive and continued association between BP values and the occurrence of heart attacks and strokes.
Artery stiffening (AS) and increased pulsatile diameter were identified as standard features of hypertension in individuals aged between 40 and 50 years, and have emerged as two of the most valuable, distinctive, and independent predictors of cardiovascular events.
Considering that pulse waves from the aorta travel to the peripheral arterial vessels more quickly in stiffer vessels, some authors suggested, in 1987, that aortic pulse wave velocity (PWV) could give reliable information about arterial stiffness. In the last few decades, due to numerous studies demonstrating that carotid-femoral PWV (cf-PWV) is a strong independent predictor of total mortality and major cardiovascular (CV) events, PWV has become a gold standard biological marker of arterial stiffness.
Therefore, in medical literature, arterial stiffness has long been strongly associated with pulse wave velocity (PWV). PWV is calculated as the distance traveled by the arterial pulse between proximal and distal vascular sites by the corresponding time interval. Currently, invasive catheter-based PWV measurement is used only in validation studies due to its complexity, high cost, and ethical limitations. Over the last two decades, several noninvasive devices for measuring PWV have been validated in published studies.
Simultaneous carotid and femoral artery measurement is the non-invasive reference for studies involving cf-PWV. Two investigators should conduct the measurement, ensuring a minimum recording time of 10 cardiac cycles. Ideally, measurements should be performed at the same time; ECG-gated sequential measurements are the second-best alternative. The recordings from the right carotid and right femoral arteries are preferred. Transit time should be determined using the intersecting tangent method. Commercial devices that currently fulfill these criteria are the Complior Analyze device (Alam Medical, Saint Quentin Fallavier, France) and the original Sphygmocor system that used tonometry for both carotid and femoral pulse wave acquisitions (discontinued; ATCOR Medical, CardieX Pty, Ltd, Sydney, NSW, Australia).
In recent decades, new devices have enabled the measurement of PWV by recording signals at more peripheral areas using brachial cuffs. The Mobil-O-Graph is one of them. It is an automated oscillometric brachial cuff-based ambulatory BP monitoring device that can measure PWV (br-PWV) by proprietary algorithms. The br-PWV can independently predict mortality in chronic kidney disease (CKD) stage 2-4. It is also associated with an increased risk of cardiovascular events and all-cause mortality in hemodialysis patients.
Additionally, mathematical formulas can estimate PWV (ePWV) based on the Reference Values for Arterial Stiffness Collaboration, published nearly fifteen years ago. The aim of this publication was to define the determinants and reference values of cf-PWV. This study demonstrated age and BP accounted for PWV and its variance in a population. Therefore, the authors proposed two formulas that used mean BP and age to calculate cf-PWV.
Analyses of data from two European populations demonstrated that e-PWV was able to predict major cardiovascular events regardless of the Systematic COronary Risk Evaluation (SCORE), the Framingham risk score (FRS), and the cf-PWV. Another recent study found an association between ePWV and CV diseases and all-cause mortality in a Chinese population, independent of CV risk factors. In addition, ePWV predicted cardiovascular events and mortality in patients with suspected coronary artery disease, and it also improved risk stratification in hospitalized COVID-19 patients, beyond conventional risk factors and scores.
Therefore, since the Mobil-o-Graph device measures PWV using an algorithm based on age and BP values, it is an expensive option. In contrast, e-PWV estimates pulse wave velocity solely through mathematical formulas. This study aimed to evaluate the correlation between the ePWV and br-PWV with the gold standard cf-PWV.
• METHODS Population and Location Subjects were selected from a health center specializing in diagnosing and treating non-communicable diseases in the city of Uberaba, Brazil, who were referred to undergo ambulatory blood pressure monitoring (ABPM) to confirm a hypertension diagnosis or evaluate uncontrolled hypertension.
Data Collection Demographic and clinical data were collected from all subjects, including previous reports of acute myocardial infarction, acute coronary syndrome, coronary or other arterial revascularization, stroke, transient ischemic attack, aortic aneurysm, peripheral artery disease, and severe chronic kidney disease (CKD). They also had their weight, height, and waist circumference measured. A nursing assistant conducted BP measurements and pulse wave analyses (PWA).
Blood Pressure Measurement
The office BP (OBP) measurements followed recommended guidelines to ensure accurate pressure values. A nursing assistant operated a Microlife device model AFIB BPA200 (Onbo Electronic Co, Shenzhen, China). This device operates in Microlife Average Mode, which takes three consecutive measurements and calculates the average BP value. The nursing assistant took one set of three BP measurements.
Carotid-Femoral Pulse Wave Analyses
After having their BP measured, participants rested for 10 minutes in the supine position. The assistant then performed the pulse wave analyses (PWA) utilizing a Complior Analyze device (ALAM MEDICAL, Saint Quentin Fallavier, France). The determination of PWA followed all the standards set in the 2012 Expert Consensus Document for measuring Aortic Stiffness, including conducting procedures in a quiet room with stable temperature. The device uses non-invasive pressure sensors to record arterial pulse simultaneously. One sensor was positioned at the carotid artery site, and the other at the femoral artery site, on the dominant side of the body. Complior automatically calculated PWV as PWV =ΔL/ΔT, where ΔT represents the transit time and ΔL being the effective distance between the two recording sites. Transit time was measured using the intersecting tangent method, and the distance was estimated as 0.8× the measured carotid-femoral distance.
Brachial Pulse Wave Analyses
Finally, for data collection, all subjects recorded twenty-four hours of ABPM utilizing a Dyna-Mapa monitor (Cardios, São Paulo, Brazil), equipped with an appropriately-sized cuff on their non-dominant arm. The device was set up to take both BP and br-PWV readings every 20 minutes throughout the day (7 AM to 11 PM). During the night (11 PM to 7 AM), BP was measured every 30 minutes, and br-PWV was measured hourly. For ABPM analyses, 'night' was defined as the period between going to bed and waking up. All recommended protocols were strictly followed in order to ensure quality recordings.
Calculation of Estimated Pulse Wave Velocity To determine the appropriate equation for calculating ePWV, we assessed the prevalence of healthy and at-risk individuals in the sample population. Healthy individuals were those who presented no risk factors and a non-elevated BP (\< 140 and 90 mmHg). On the other hand, the at-risk group included individuals with elevated BP (\>140 or 90 mmHg) or at least one risk factor, such as history of hypertension, dyslipidemia, diabetes, smoking, obesity (BMI ≥ 30 kg/m2), abdominal waist circumference at risk (\> 102 cm in males, \> 88 cm in females). Therefore, we calculated e-PWV using equations 1 and 2, derived from the Reference Values for Arterial Stiffness Collaboration, based on age and MBP, as follows.
At-risk individuals: e-PWV = 9.58748315543126-0.402467539733184\*age+4.56020798207263\*10-3\*age2-2.6207705511664\*10-5\*age2\*MBP+3.1762450559276\*10-3\*age\*MBP-1.832150382185\*10-2\*MBP.
Healthy individuals: e-PWV = 4.62 - 0.13\*age + 0.0018\*age\^2 + 0.0006\*age\*MBP + 0.0284\*MBP We used the average of the first three BP measurements to estimate MBP, which was calculated as 40% of office pulse pressure plus diastolic BP; MBP = diastolic BP+ 0.4\*(systolic BP- diastolic BP).
Statistical Analysis
The normal distribution of the variables will be analyzed. Depending on the results, data will be expressed through proportions, mean, or median. We will apply the chi-squared test to compare proportions. If the distribution is normal, we will use the concordance correlation coefficient (Pc) to assess the association, precision (p), and accuracy among cf-PWV, br-PWV, and e-PWV. If the distribution is abnormal, we will use the Rank correlation to assess the relationship among all PWV metrics. Additionally, we will use a Bland-Altman plot to investigate the agreement among cf-PWV, br-PWV, and e-PWV values.
The databases will be built using Microsoft Excel, and the statistical analyses will be conducted using MedCalc. All participants will provide written informed consent to participate in the study.
Artery stiffening (AS) and increased pulsatile diameter were identified as standard features of hypertension in individuals aged between 40 and 50 years, and have emerged as two of the most valuable, distinctive, and independent predictors of cardiovascular events.
Considering that pulse waves from the aorta travel to the peripheral arterial vessels more quickly in stiffer vessels, some authors suggested, in 1987, that aortic pulse wave velocity (PWV) could give reliable information about arterial stiffness. In the last few decades, due to numerous studies demonstrating that carotid-femoral PWV (cf-PWV) is a strong independent predictor of total mortality and major cardiovascular (CV) events, PWV has become a gold standard biological marker of arterial stiffness.
Therefore, in medical literature, arterial stiffness has long been strongly associated with pulse wave velocity (PWV). PWV is calculated as the distance traveled by the arterial pulse between proximal and distal vascular sites by the corresponding time interval. Currently, invasive catheter-based PWV measurement is used only in validation studies due to its complexity, high cost, and ethical limitations. Over the last two decades, several noninvasive devices for measuring PWV have been validated in published studies.
Simultaneous carotid and femoral artery measurement is the non-invasive reference for studies involving cf-PWV. Two investigators should conduct the measurement, ensuring a minimum recording time of 10 cardiac cycles. Ideally, measurements should be performed at the same time; ECG-gated sequential measurements are the second-best alternative. The recordings from the right carotid and right femoral arteries are preferred. Transit time should be determined using the intersecting tangent method. Commercial devices that currently fulfill these criteria are the Complior Analyze device (Alam Medical, Saint Quentin Fallavier, France) and the original Sphygmocor system that used tonometry for both carotid and femoral pulse wave acquisitions (discontinued; ATCOR Medical, CardieX Pty, Ltd, Sydney, NSW, Australia).
In recent decades, new devices have enabled the measurement of PWV by recording signals at more peripheral areas using brachial cuffs. The Mobil-O-Graph is one of them. It is an automated oscillometric brachial cuff-based ambulatory BP monitoring device that can measure PWV (br-PWV) by proprietary algorithms. The br-PWV can independently predict mortality in chronic kidney disease (CKD) stage 2-4. It is also associated with an increased risk of cardiovascular events and all-cause mortality in hemodialysis patients.
Additionally, mathematical formulas can estimate PWV (ePWV) based on the Reference Values for Arterial Stiffness Collaboration, published nearly fifteen years ago. The aim of this publication was to define the determinants and reference values of cf-PWV. This study demonstrated age and BP accounted for PWV and its variance in a population. Therefore, the authors proposed two formulas that used mean BP and age to calculate cf-PWV.
Analyses of data from two European populations demonstrated that e-PWV was able to predict major cardiovascular events regardless of the Systematic COronary Risk Evaluation (SCORE), the Framingham risk score (FRS), and the cf-PWV. Another recent study found an association between ePWV and CV diseases and all-cause mortality in a Chinese population, independent of CV risk factors. In addition, ePWV predicted cardiovascular events and mortality in patients with suspected coronary artery disease, and it also improved risk stratification in hospitalized COVID-19 patients, beyond conventional risk factors and scores.
Therefore, since the Mobil-o-Graph device measures PWV using an algorithm based on age and BP values, it is an expensive option. In contrast, e-PWV estimates pulse wave velocity solely through mathematical formulas. This study aimed to evaluate the correlation between the ePWV and br-PWV with the gold standard cf-PWV.
• METHODS Population and Location Subjects were selected from a health center specializing in diagnosing and treating non-communicable diseases in the city of Uberaba, Brazil, who were referred to undergo ambulatory blood pressure monitoring (ABPM) to confirm a hypertension diagnosis or evaluate uncontrolled hypertension.
Data Collection Demographic and clinical data were collected from all subjects, including previous reports of acute myocardial infarction, acute coronary syndrome, coronary or other arterial revascularization, stroke, transient ischemic attack, aortic aneurysm, peripheral artery disease, and severe chronic kidney disease (CKD). They also had their weight, height, and waist circumference measured. A nursing assistant conducted BP measurements and pulse wave analyses (PWA).
Blood Pressure Measurement
The office BP (OBP) measurements followed recommended guidelines to ensure accurate pressure values. A nursing assistant operated a Microlife device model AFIB BPA200 (Onbo Electronic Co, Shenzhen, China). This device operates in Microlife Average Mode, which takes three consecutive measurements and calculates the average BP value. The nursing assistant took one set of three BP measurements.
Carotid-Femoral Pulse Wave Analyses
After having their BP measured, participants rested for 10 minutes in the supine position. The assistant then performed the pulse wave analyses (PWA) utilizing a Complior Analyze device (ALAM MEDICAL, Saint Quentin Fallavier, France). The determination of PWA followed all the standards set in the 2012 Expert Consensus Document for measuring Aortic Stiffness, including conducting procedures in a quiet room with stable temperature. The device uses non-invasive pressure sensors to record arterial pulse simultaneously. One sensor was positioned at the carotid artery site, and the other at the femoral artery site, on the dominant side of the body. Complior automatically calculated PWV as PWV =ΔL/ΔT, where ΔT represents the transit time and ΔL being the effective distance between the two recording sites. Transit time was measured using the intersecting tangent method, and the distance was estimated as 0.8× the measured carotid-femoral distance.
Brachial Pulse Wave Analyses
Finally, for data collection, all subjects recorded twenty-four hours of ABPM utilizing a Dyna-Mapa monitor (Cardios, São Paulo, Brazil), equipped with an appropriately-sized cuff on their non-dominant arm. The device was set up to take both BP and br-PWV readings every 20 minutes throughout the day (7 AM to 11 PM). During the night (11 PM to 7 AM), BP was measured every 30 minutes, and br-PWV was measured hourly. For ABPM analyses, 'night' was defined as the period between going to bed and waking up. All recommended protocols were strictly followed in order to ensure quality recordings.
Calculation of Estimated Pulse Wave Velocity To determine the appropriate equation for calculating ePWV, we assessed the prevalence of healthy and at-risk individuals in the sample population. Healthy individuals were those who presented no risk factors and a non-elevated BP (\< 140 and 90 mmHg). On the other hand, the at-risk group included individuals with elevated BP (\>140 or 90 mmHg) or at least one risk factor, such as history of hypertension, dyslipidemia, diabetes, smoking, obesity (BMI ≥ 30 kg/m2), abdominal waist circumference at risk (\> 102 cm in males, \> 88 cm in females). Therefore, we calculated e-PWV using equations 1 and 2, derived from the Reference Values for Arterial Stiffness Collaboration, based on age and MBP, as follows.
At-risk individuals: e-PWV = 9.58748315543126-0.402467539733184\*age+4.56020798207263\*10-3\*age2-2.6207705511664\*10-5\*age2\*MBP+3.1762450559276\*10-3\*age\*MBP-1.832150382185\*10-2\*MBP.
Healthy individuals: e-PWV = 4.62 - 0.13\*age + 0.0018\*age\^2 + 0.0006\*age\*MBP + 0.0284\*MBP We used the average of the first three BP measurements to estimate MBP, which was calculated as 40% of office pulse pressure plus diastolic BP; MBP = diastolic BP+ 0.4\*(systolic BP- diastolic BP).
Statistical Analysis
The normal distribution of the variables will be analyzed. Depending on the results, data will be expressed through proportions, mean, or median. We will apply the chi-squared test to compare proportions. If the distribution is normal, we will use the concordance correlation coefficient (Pc) to assess the association, precision (p), and accuracy among cf-PWV, br-PWV, and e-PWV. If the distribution is abnormal, we will use the Rank correlation to assess the relationship among all PWV metrics. Additionally, we will use a Bland-Altman plot to investigate the agreement among cf-PWV, br-PWV, and e-PWV values.
The databases will be built using Microsoft Excel, and the statistical analyses will be conducted using MedCalc. All participants will provide written informed consent to participate in the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Hypertension
Arterial Stiffness
Pulse Wave Analysis
Pulse Wave Velocity
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Adults older than eighteen with elevated office BP, treated and untreated.
All participants were referred by a physician to perform ambulatory blood pressure monitoring (ABPM) to confirm a hypertension diagnosis or evaluate uncontrolled hypertension.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
\- Individuals older than 18 with an elevated office blood pressure :
* suspected hypertension diagnosis or
* uncontrolled hypertension under treatment
* suspected hypertension diagnosis or
* uncontrolled hypertension under treatment
Exclusion Criteria
24-hour ABPM recordings presenting:
* less than 70% of the expected measurements or
* fewer than 20 valid awake or seven valid sleeping measurements or
* fewer than two valid daytime and one valid night-time measurement per hour
* less than 70% of the expected measurements or
* fewer than 20 valid awake or seven valid sleeping measurements or
* fewer than two valid daytime and one valid night-time measurement per hour
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital de Base
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
JOSE FERNANDO VILELA-MARTIN
PhD
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CDC center
Uberaba, Minas Gerais, Brazil
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Brazil
References
Explore related publications, articles, or registry entries linked to this study.
Silva MA, Oliveira AP, Queiroz AC, Spaziani AO, Fernandes LA, De Oliveira KA, Lopes VDS, Landim MP, Cosenso-Martin LN, Vilela-Martin JF. Correlation between estimated pulse wave velocity values from two equations in healthy and under cardiovascular risk populations. PLoS One. 2024 Apr 9;19(4):e0298405. doi: 10.1371/journal.pone.0298405. eCollection 2024.
Reference Type
BACKGROUND
Stergiou GS, Palatini P, Parati G, O'Brien E, Januszewicz A, Lurbe E, Persu A, Mancia G, Kreutz R; European Society of Hypertension Council and the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens. 2021 Jul 1;39(7):1293-1302. doi: 10.1097/HJH.0000000000002843. No abstract available.
Reference Type
BACKGROUND
Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, Filipovsky J, Huybrechts S, Mattace-Raso FU, Protogerou AD, Schillaci G, Segers P, Vermeersch S, Weber T; Artery Society; European Society of Hypertension Working Group on Vascular Structure and Function; European Network for Noninvasive Investigation of Large Arteries. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012 Mar;30(3):445-8. doi: 10.1097/HJH.0b013e32834fa8b0.
Reference Type
BACKGROUND
McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, Christodorescu RM, Daskalopoulou SS, Ferro CJ, Gerdts E, Hanssen H, Harris J, Lauder L, McManus RJ, Molloy GJ, Rahimi K, Regitz-Zagrosek V, Rossi GP, Sandset EC, Scheenaerts B, Staessen JA, Uchmanowicz I, Volterrani M, Touyz RM; ESC Scientific Document Group. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024 Oct 7;45(38):3912-4018. doi: 10.1093/eurheartj/ehae178. No abstract available.
Reference Type
BACKGROUND
Stamatelopoulos K, Georgiopoulos G, Baker KF, Tiseo G, Delialis D, Lazaridis C, Barbieri G, Masi S, Vlachogiannis NI, Sopova K, Mengozzi A, Ghiadoni L, Schim van der Loeff I, Hanrath AT, Ajdini B, Vlachopoulos C, Dimopoulos MA, Duncan CJA, Falcone M, Stellos K; Pisa COVID-19 Research Group; Newcastle COVID-19 Research Group. Estimated pulse wave velocity improves risk stratification for all-cause mortality in patients with COVID-19. Sci Rep. 2021 Oct 12;11(1):20239. doi: 10.1038/s41598-021-99050-0.
Reference Type
BACKGROUND
Greve SV, Blicher MK, Kruger R, Sehestedt T, Gram-Kampmann E, Rasmussen S, Vishram JK, Boutouyrie P, Laurent S, Olsen MH. Estimated carotid-femoral pulse wave velocity has similar predictive value as measured carotid-femoral pulse wave velocity. J Hypertens. 2016 Jul;34(7):1279-89. doi: 10.1097/HJH.0000000000000935.
Reference Type
BACKGROUND
Hametner B, Wassertheurer S, Mayer CC, Danninger K, Binder RK, Weber T. Aortic Pulse Wave Velocity Predicts Cardiovascular Events and Mortality in Patients Undergoing Coronary Angiography: A Comparison of Invasive Measurements and Noninvasive Estimates. Hypertension. 2021 Feb;77(2):571-581. doi: 10.1161/HYPERTENSIONAHA.120.15336. Epub 2021 Jan 4.
Reference Type
BACKGROUND
Reference Values for Arterial Stiffness' Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. Eur Heart J. 2010 Oct;31(19):2338-50. doi: 10.1093/eurheartj/ehq165. Epub 2010 Jun 7.
Reference Type
BACKGROUND
Sarafidis PA, Loutradis C, Karpetas A, Tzanis G, Piperidou A, Koutroumpas G, Raptis V, Syrgkanis C, Liakopoulos V, Efstratiadis G, London G, Zoccali C. Ambulatory Pulse Wave Velocity Is a Stronger Predictor of Cardiovascular Events and All-Cause Mortality Than Office and Ambulatory Blood Pressure in Hemodialysis Patients. Hypertension. 2017 Jul;70(1):148-157. doi: 10.1161/HYPERTENSIONAHA.117.09023. Epub 2017 May 8.
Reference Type
BACKGROUND
Baumann M, Wassertheurer S, Suttmann Y, Burkhardt K, Heemann U. Aortic pulse wave velocity predicts mortality in chronic kidney disease stages 2-4. J Hypertens. 2014 Apr;32(4):899-903. doi: 10.1097/HJH.0000000000000113.
Reference Type
BACKGROUND
Salvi P, Scalise F, Rovina M, Moretti F, Salvi L, Grillo A, Gao L, Baldi C, Faini A, Furlanis G, Sorropago A, Millasseau SC, Sorropago G, Carretta R, Avolio AP, Parati G. Noninvasive Estimation of Aortic Stiffness Through Different Approaches. Hypertension. 2019 Jul;74(1):117-129. doi: 10.1161/HYPERTENSIONAHA.119.12853. Epub 2019 May 28.
Reference Type
BACKGROUND
Spronck B, Terentes-Printzios D, Avolio AP, Boutouyrie P, Guala A, Jeroncic A, Laurent S, Barbosa ECD, Baulmann J, Chen CH, Chirinos JA, Daskalopoulou SS, Hughes AD, Mahmud A, Mayer CC, Park JB, Pierce GL, Schutte AE, Urbina EM, Wilkinson IB, Segers P, Sharman JE, Tan I, Vlachopoulos C, Weber T, Bianchini E, Bruno RM; Association for Research into Arterial Structure and Physiology (ARTERY), the European Society of Hypertension Working Group on Large Arteries, European Cooperation in Science and Technology (COST) Action VascAgeNet, North American Artery Society, ARTERY LATAM, Pulse of Asia, and Society for Arterial Stiffness-Germany-Austria-Switzerland (DeGAG). 2024 Recommendations for Validation of Noninvasive Arterial Pulse Wave Velocity Measurement Devices. Hypertension. 2024 Jan;81(1):183-192. doi: 10.1161/HYPERTENSIONAHA.123.21618. Epub 2023 Nov 17.
Reference Type
BACKGROUND
Segers P, Rietzschel ER, Chirinos JA. How to Measure Arterial Stiffness in Humans. Arterioscler Thromb Vasc Biol. 2020 May;40(5):1034-1043. doi: 10.1161/ATVBAHA.119.313132. Epub 2019 Dec 26.
Reference Type
BACKGROUND
Townsend RR, Wilkinson IB, Schiffrin EL, Avolio AP, Chirinos JA, Cockcroft JR, Heffernan KS, Lakatta EG, McEniery CM, Mitchell GF, Najjar SS, Nichols WW, Urbina EM, Weber T; American Heart Association Council on Hypertension. Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness: A Scientific Statement From the American Heart Association. Hypertension. 2015 Sep;66(3):698-722. doi: 10.1161/HYP.0000000000000033. Epub 2015 Jul 9. No abstract available.
Reference Type
BACKGROUND
Safar ME, Toto-Moukouo JJ, Bouthier JA, Asmar RE, Levenson JA, Simon AC, London GM. Arterial dynamics, cardiac hypertrophy, and antihypertensive treatment. Circulation. 1987 Jan;75(1 Pt 2):I156-61.
Reference Type
BACKGROUND
Ben-Shlomo Y, Spears M, Boustred C, May M, Anderson SG, Benjamin EJ, Boutouyrie P, Cameron J, Chen CH, Cruickshank JK, Hwang SJ, Lakatta EG, Laurent S, Maldonado J, Mitchell GF, Najjar SS, Newman AB, Ohishi M, Pannier B, Pereira T, Vasan RS, Shokawa T, Sutton-Tyrell K, Verbeke F, Wang KL, Webb DJ, Willum Hansen T, Zoungas S, McEniery CM, Cockcroft JR, Wilkinson IB. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol. 2014 Feb 25;63(7):636-646. doi: 10.1016/j.jacc.2013.09.063. Epub 2013 Nov 13.
Reference Type
BACKGROUND
Safar ME, Asmar R, Benetos A, Blacher J, Boutouyrie P, Lacolley P, Laurent S, London G, Pannier B, Protogerou A, Regnault V; French Study Group on Arterial Stiffness. Interaction Between Hypertension and Arterial Stiffness. Hypertension. 2018 Oct;72(4):796-805. doi: 10.1161/HYPERTENSIONAHA.118.11212. No abstract available.
Reference Type
BACKGROUND
Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002 Dec 14;360(9349):1903-13. doi: 10.1016/s0140-6736(02)11911-8.
Reference Type
BACKGROUND
Franklin SS, Gustin W 4th, Wong ND, Larson MG, Weber MA, Kannel WB, Levy D. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation. 1997 Jul 1;96(1):308-15. doi: 10.1161/01.cir.96.1.308.
Reference Type
BACKGROUND
Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020 Apr;16(4):223-237. doi: 10.1038/s41581-019-0244-2. Epub 2020 Feb 5.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
https://plataformabrasil.saude.gov.br/visao/pesquisador/gerirPesquisa/gerirPesquisaAgrupador.jsf
Plataforma Brasil CAAE number : 57703722.7.0000.5415
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
cfPWV, brPWV and ePWV
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Augmented Velocity Index of Intra-abdominal, Carotid and Retinal Arteries
NCT05273905
UNKNOWN
Comparison Between Main Branch and Side Branch Vessels
NCT01046409
UNKNOWN
Analysis of Respiratory Variations of the Right Internal Jugular Vein as a Predictor of Fluid Responsiveness During Mechanical Ventilation
NCT03030898
UNKNOWN
NA
Subclavian Versus Inferior Vena Cava Collapsibility Indices.
NCT03337386
COMPLETED
NA
Hemodynamic Measurements at Different Inclinations of the Head
NCT02046785
UNKNOWN
NA
Accuracy of IVCCI as a Measure of CVP
NCT06166875
COMPLETED
Comparing Palpation Guided and Ultrasound Guided Arterial Line Placement
NCT01757314
TERMINATED
A Comparative Study of Portable Patch-type Carotid Ultrasound CADFlow and Desktop Ultrasound Machines
NCT07197411
NOT_YET_RECRUITING
Hemodynamic Parameters Assessment; Invasive Versus Noninvasive
NCT06198621
NOT_YET_RECRUITING
Laser-assisted Ultrasound-guided Peripheral Vein Cannulation in Cardiac Surgery
NCT07079904
RECRUITING
NA
The Effect of Head and Shoulder Positioning on the Cross-sectional Area of the Subclavian Vein in Obese Adults
NCT03993587
COMPLETED
Perfusion Index and End Diastolic Velocity Ratios as Predictors of Supraclavicular Block Success in Vascular Access Surgery
NCT07197281
NOT_YET_RECRUITING
Correlation Between Popliteal Vein Compliance and Venous Clinical Severity Score
NCT06175481
COMPLETED
Comparison of Hemodynamic Variables Between Using Conventional Invasive Catheter Monitoring and Non-invasive Piezoelectric Sensor
NCT07110506
NOT_YET_RECRUITING
NA
A New Technique for Determining Limb Occlusion Pressure
NCT02620722
COMPLETED
NA
Correlation Between Peripheral Venous Pressure and Central Venous Pressure in the Cardiac Intensive Care Unit
NCT03526497
TERMINATED
Brachial Artery Pulsatility Index in Supraclavicular Block
NCT06475638
COMPLETED
Accuracy of CVC Depth Prediction in Internal Jugular Veins: The Difference Between The Andropoulos and ECG Methods
NCT04215250
COMPLETED
NA
Cardio-ankle Vascular Index (CAVI) in Hypertension Patients After One Year of Treatment
NCT03680313
COMPLETED
Identification of Carotid Vasa Vasorum and Correlation With Acute Coronary Events
NCT01436773
COMPLETED
Color Doppler and Peripheral Venous Catheters
NCT03889678
COMPLETED
Noninvasive Monitoring in Lower Body Negative and Positive Pressure Tests
NCT03671902
COMPLETED
NA
The Relation Between Common Carotid Artery Diameter and Central Venous Pressure for Assessment of Intravascular Fluid Status After Major Surgeries: An Observational Study
NCT04018443
UNKNOWN
Capillary and Venous Blood Count Parameters
NCT00390988
COMPLETED
Accuracy of Non-Invasive Blood Pressure Measurements at the Arm, Calf , and Finger
NCT04269382
COMPLETED
NA